menu
    • menu
    [{"orgOrder":0,"company":"Aperta Biosciences, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Spinosyn D","moa":"Nicotinic acetylcholine receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aperta Biosciences, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Aperta Biosciences, LLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aperta Biosciences, LLC \/ Undisclosed"},{"orgOrder":0,"company":"ParaPRO","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Spinosyn D","moa":"Nicotinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"ParaPRO","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"ParaPRO \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"ParaPRO \/ Undisclosed"},{"orgOrder":0,"company":"CIPHER PHARMS INC","sponsor":"Concentrics Research | IQVIA | Medpace, Inc | Inotiv | BioAgilytix","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Spinosyn D","moa":"Nicotinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"CIPHER PHARMS INC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"CIPHER PHARMS INC \/ Concentrics Research | IQVIA | Medpace, Inc | Inotiv | BioAgilytix","highestDevelopmentStatusID":"11","companyTruncated":"CIPHER PHARMS INC \/ Concentrics Research | IQVIA | Medpace, Inc | Inotiv | BioAgilytix"},{"orgOrder":0,"company":"ParaPRO","sponsor":"Concentrics Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Spinosyn D","moa":"Nicotinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"ParaPRO","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"ParaPRO \/ Concentrics Research","highestDevelopmentStatusID":"10","companyTruncated":"ParaPRO \/ Concentrics Research"},{"orgOrder":0,"company":"ParaPRO","sponsor":"Concentrics Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Spinosyn D","moa":"Nicotinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"ParaPRO","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"ParaPRO \/ Concentrics Research","highestDevelopmentStatusID":"10","companyTruncated":"ParaPRO \/ Concentrics Research"}]

    Find Clinical Drug Pipeline Developments & Deals for Spinosad

    Menu

    Spinosad

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aperta Biosciences, LLC

                            Country arrow
                            AAPS
                            Not Confirmed

                            Aperta Biosciences, LLC

                            Country arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Spinosyn D

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Nove...

                            Details : Spinosad is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Blepharitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 06, 2024

                            Lead Product(s) : Spinosyn D

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CIPHER PHARMS INC

                            Canada arrow
                            AAPS
                            Not Confirmed

                            CIPHER PHARMS INC

                            Canada arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Spinosyn D

                            Therapeutic Area : Dermatology

                            Study Phase : Phase IV

                            Sponsor : Concentrics Research | IQVIA | Medpace, Inc | Inotiv | BioAgilytix

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age With Sc...

                            Details : Spinosad is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Scabies.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 05, 2022

                            Lead Product(s) : Spinosyn D

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase IV

                            Sponsor : Concentrics Research | IQVIA | Medpace, Inc | Inotiv | BioAgilytix

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ParaPRO

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            ParaPRO

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Spinosyn D

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Concentrics Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies

                            Details : Natroba (Spinosad) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Scabies.

                            Product Name : Natroba

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 30, 2015

                            Lead Product(s) : Spinosyn D

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Concentrics Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ParaPRO

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            ParaPRO

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Spinosyn D

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Concentrics Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies

                            Details : Natroba (Spinosad) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Scabies.

                            Product Name : Natroba

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 30, 2015

                            Lead Product(s) : Spinosyn D

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Concentrics Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ParaPRO

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            ParaPRO

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Spinosyn D

                            Therapeutic Area : Dermatology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetic (PK) and Tolerance Study of Natroba Topical Suspension in Pediatrics With an Active Head Lice ...

                            Details : Spinosad is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Lice Infestations.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 08, 2012

                            Lead Product(s) : Spinosyn D

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth